Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

December 30, 2025

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Semaglutide Injection

"The subject will receive either a dose of semaglutide subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."

DRUG

Semaglutide Injection(Ozempic®)

"The subject will receive either a dose of Ozempic® subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."

DRUG

Metformin

"Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks."

All Listed Sponsors
lead

Chengdu Brilliant Pharmaceutical Co., Ltd.

INDUSTRY

NCT06339086 - Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter